Home > Cardiology > AHA 2019 > New Approaches to CVD Risk Reduction > Phase 3 BETonMACE trial did not meet its primary endpoint

Phase 3 BETonMACE trial did not meet its primary endpoint

Presented By
Prof. Kausik K. Ray, Imperial College London, United Kingdom
Conference
AHA 2019
Trial
Phase 3, BETonMACE

The results of a placebo-controlled trial showed that apabetalone does not decrease cardiovascular (CV) death, non-fatal myocardial infarction (MI), or non-fatal stroke in diabetic patients with recent acute coronary syndrome (ACS).

Prof. Kausik K. Ray (Imperial College London, United Kingdom) presented the results of the phase 3, international, multicentre, randomised, double-blind, placebo-controlled BETonMACE trial. This study aimed to determine whether modulating epigenetics with the selective bromodomain and extra-terminal (BET) protein inhibitor apabetalone is safe and effective in reducing CV risk [1]. Patients with type 2 diabetes mellitus, ACS within the preceding 7-90 days, and low HDL-C (≤40 mg/dl for men and ≤45 mg/dl for women) were randomised to receive either apabetalone (100 mg orally, twice a day; n=1,212) or matched placebo (n=1,206) in addition to standard-of-care therapy, e.g...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on